Latest Information Update: 03 Mar 2016
At a glance
- Originator Boehringer Ingelheim
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 25 Feb 2016 Preclinical trials in Undefined indication in Germany (PO)
- 25 Feb 2016 Boehringer Ingelheim plans a phase I study in Healthy volunteers in Germany (NCT02694354)